ES2113904T3 - ANTHRACICLIN DRUGS. - Google Patents

ANTHRACICLIN DRUGS.

Info

Publication number
ES2113904T3
ES2113904T3 ES92115600T ES92115600T ES2113904T3 ES 2113904 T3 ES2113904 T3 ES 2113904T3 ES 92115600 T ES92115600 T ES 92115600T ES 92115600 T ES92115600 T ES 92115600T ES 2113904 T3 ES2113904 T3 ES 2113904T3
Authority
ES
Spain
Prior art keywords
antibody
enzyme
products
tumor cells
anthraciclin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES92115600T
Other languages
Spanish (es)
Inventor
Peter D Senter
Mark G Saulnier
Joseph P Brown
David E Kerr
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US07/211,301 external-priority patent/US4975278A/en
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Priority claimed from EP88112646A external-priority patent/EP0302473B1/en
Application granted granted Critical
Publication of ES2113904T3 publication Critical patent/ES2113904T3/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6891—Pre-targeting systems involving an antibody for targeting specific cells
    • A61K47/6899—Antibody-Directed Enzyme Prodrug Therapy [ADEPT]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/20—Carbocyclic rings
    • C07H15/24—Condensed ring systems having three or more rings
    • C07H15/252—Naphthacene radicals, e.g. daunomycins, adriamycins

Landscapes

  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nanotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Immunology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

ESTA INVENCION SE REFIERE A PROMEDICAMENTOS DE ANTRACICLINA QUE PERMITEN EL SUMINISTRO DE MEDICAMENTOS CITOTOXICOS A LAS CELULAS TUMORALES MEDIANTE LA ADMINISTRACION DE UN CONJUGADO DE ANTICUERPO Y ENZIMA ESPECIFICO PARA LOS TUMORES QUE SE UNE A LAS CELULAS TUMORALES Y LA ADMINISTRACION ADICIONAL DEL PROMEDICAMENTO, QUE ES CONVERTIDO EN EL LUGAR DONDE SE ENCUENTRA EL TUMOR, ANTE LA PRESENCIA DE LA ENZIMA UNIDA AL ANTICUERPO, EN UN MEDICAMENTO CITOTOXICO ACTIVO. LA PRESENTE INVENCION SE REFIERE TAMBIEN A UN METODO PARA LA PREPARACION DE ESTOS PROMEDICAMENTOS. SEGUN UN ASPECTO DE LA INVENCION, SE HA UTILIZADO UN CONGUJADO DE ANTICUERPO Y ENZIMA QUE CONTIENE LA ENZIMA AMIDASA DE LA PENICILINA V ("PVA") JUNTO CON UN NUEVO PROMEDICAMENTO, N AS TUMORALES. LOS PRODUCTOS DE ESTA INVENCION PUEDEN MATAR SELECTIVAMENTE, EN MAYOR MEDIDA, LAS CELULAS TUMORALES Y POR TANTO SON UTILES EN EL TRATAMIENTO DE CANCERES Y DE OTROS TUMORES.THIS INVENTION IS RELATED TO ANTHRACICLINE PROMEDICATIONS THAT ALLOW THE SUPPLY OF CYTOTOXIC MEDICINES TO TUMOR CELLS THROUGH THE ADMINISTRATION OF AN ANTIBODY AND LAYDUARY ADEIRA, AND ADUTICAL LAYDOM ADJUSTED IN THE PLACE WHERE THE TUMOR IS FOUND, BEFORE THE PRESENCE OF THE ENZYME LINKED TO THE ANTIBODY, IN AN ACTIVE CYTOTOXIC MEDICINE. THE PRESENT INVENTION ALSO REFERS TO A METHOD FOR THE PREPARATION OF THESE PRODUCTS. ACCORDING TO AN ASPECT OF THE INVENTION, AN ANTIBODY AND ENZYME CONJUGATE CONTAINING THE PENICILIN V ("PVA") ENZYME AMIDASE HAS BEEN USED, WITH A NEW PRODUCT, N AS TUMORALS. THE PRODUCTS OF THIS INVENTION MAY SELECTIVELY KILL, TO A LARGER EXTENT, TUMOR CELLS AND THEREFORE ARE USEFUL IN THE TREATMENT OF CANCERS AND OTHER TUMORS.

ES92115600T 1987-08-04 1988-08-03 ANTHRACICLIN DRUGS. Expired - Lifetime ES2113904T3 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US8138287A 1987-08-04 1987-08-04
US16106888A 1988-02-26 1988-02-26
US07/211,301 US4975278A (en) 1988-02-26 1988-06-29 Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells
EP88112646A EP0302473B1 (en) 1987-08-04 1988-08-03 Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells

Publications (1)

Publication Number Publication Date
ES2113904T3 true ES2113904T3 (en) 1998-05-16

Family

ID=27441445

Family Applications (1)

Application Number Title Priority Date Filing Date
ES92115600T Expired - Lifetime ES2113904T3 (en) 1987-08-04 1988-08-03 ANTHRACICLIN DRUGS.

Country Status (2)

Country Link
ES (1) ES2113904T3 (en)
GR (1) GR3026444T3 (en)

Also Published As

Publication number Publication date
GR3026444T3 (en) 1998-06-30

Similar Documents

Publication Publication Date Title
PT88187A (en) METHOD FOR THE DISTRIBUTION OF CITOTOXIC AGENTS FOR TUMOR CELLS USING ADMINISTRATION OF ANTIBODY-ENZYME CONJUGATES IN ASSOCIATION WITH PROFITABLES WITH CYTOTOXIC ACTIVITY
Senter et al. Enhancement of the in vitro and in vivo antitumor activities of phosphorylated mitomycin C and etoposide derivatives by monoclonal antibody-alkaline phosphatase conjugates
ES2279580T3 (en) COMPOSITIONS FOR MANAGING GENES TO SKIN CELLS THAT PRESENT ANTIGENS.
PT693924E (en) PROCESSES FOR THE ADMINISTRATION (IN VIVO) OF BIOLOGICAL AND COMPOSITION SUBSTANCES USED IN THESE PROCESSES
ES2074124T5 (en) COMPOSITION IN THE FORM OF A FOAM CONTAINING 5-AMINOSALICYLIC ACID FOR INTRA-RECTAL ADMINISTRATION.
HUT43948A (en) Emulsion compositions for dosing ionizable hydrophobic medical substances which are little soluble in water and process for preparing the same
ES2060947T3 (en) A NEW ANTIBODY SUPPLY SYSTEM FOR BIOLOGICAL RESPONSE MODIFIERS.
EP0275005A3 (en) Complex compounds of bioflavonoids with phospholipids, their preparation and use, and pharmaceutical and cosmetic compositions containing them
ES2094923T3 (en) PROCEDURE FOR THE PREPARATION OF PRESERVED MEDICINES CONTAINING HUMAN PROTEINS, FOR INFUSION OR INJECTION PURPOSES.
RU94038047A (en) Drugs delivery system for their being delivered simultaneously with other enzyme- and light-activated agents
ES2080837T3 (en) TREATMENT OF STATES AND DISEASES.
ES2062700T3 (en) PROCEDURE FOR THE PREPARATION OF MEDICINES IN THE FORM OF PEARLS.
MX9703621A (en) NEW AMINO ACID DERIVATIVES WITH IMPROVED ACTIVITY FOR RESISTANCE TO MULTIPLE DRUGS.
SE8504945L (en) PHARMACEUTICAL COMPOSITIONS CONTAINING ANTRACYCLING GYCOSIDES
AR008680A1 (en) SUBSTITUTES FOR PLATELETS AND CONJUGATION METHODS SUITABLE FOR THEIR PREPARATION
ES2000743A6 (en) Pharmaceutical dosage unit.
EA199900734A1 (en) MICROCAPSULES CONTAINING CIS-PLATIN
TW202131952A (en) Interleukin 10 conjugates and uses thereof
HUP0000651A2 (en) Conjugates useful in the treatment of prostate cancer
ES2080549T3 (en) MEDICINES BASED ON POLYHYDROXYMETHYLENE DERIVATIVES, PROCEDURE FOR THEIR PREPARATION AND USE.
MY102918A (en) Purified antineoplaston fractions and methods of treating neoplastic disease.
ES2066062T3 (en) PREPARATION OF SUSTAINED RELEASE FOR ADMINISTRATION TO THE BRAIN.
NO179436C (en) Process for the manufacture of pharmaceutical products for topical use
ES2113904T3 (en) ANTHRACICLIN DRUGS.
BR0116653A (en) Medicinal product containing a polyamine as active substance

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 540859

Country of ref document: ES